Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 18, 2009 - Issue 11
Submit an article Journal homepage
151
Views
6
CrossRef citations to date
0
Altmetric
Reviews

Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the ‘age of remission’?

Robert J Moots School of Clinical Sciences at University of Liverpool, University Hospital Aintree, Liverpool, UK +44 0 151 5295889; +44 0 151 5295888; [email protected]
, PhD,
Andrew JK Östör Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, School of Clinical Medicine, Cambridge, UK
, MBBS &
John D Isaacs Newcastle University, Wilson Horne Immunotherapy Centre, Newcastle upon Tyne, UK
, PhD
Pages 1687-1699 | Published online: 28 Aug 2009

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Bernard Bannwarth & Christophe Richez. (2011) Clinical safety of tocilizumab in rheumatoid arthritis. Expert Opinion on Drug Safety 10:1, pages 123-131.
Read now
Toshio Tanaka, Atsushi Ogata & Masashi Narazaki. (2010) Tocilizumab for the treatment of rheumatoid arthritis. Expert Review of Clinical Immunology 6:6, pages 843-854.
Read now

Articles from other publishers (4)

Wen-Yuan Lee, Hsin-Yi Chen, Kuan-Chung Chen & Calvin Yu-Chian Chen. (2014) Treatment of Rheumatoid Arthritis with Traditional Chinese Medicine. BioMed Research International 2014, pages 1-11.
Crossref
Sarah Richardson & John Isaacs. (2013) Novel immunotherapies for rheumatoid arthritis. Clinical Medicine 13:4, pages 391-394.
Crossref
Salvatore Albani, Eva C. Koffeman & Berent Prakken. (2011) Induction of immune tolerance in the treatment of rheumatoid arthritis. Nature Reviews Rheumatology 7:5, pages 272-281.
Crossref
L. Campbell, C. Chen, S. S. Bhagat, R. A. Parker & A. J. K. Ostor. (2010) Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology 50:3, pages 552-562.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.